Cheryl Corcoran, M.D.
Assistant Professor of Clinical Psychiatry
Director, Center of Prevention and Evaluation,
New York State Psychiatric Institute
Dr. Corcoran is the Director of the Center of Prevention and Evaluation (COPE), a longitudinal cohort study of young people who are at increased risk for psychosis, as compared to their peers.
Her research focus is to identify biomarkers of risk and illness progression such that we can better understand who is truly at risk and develop safe and effective interventions for them. These studies include brain imaging, electrophysiology, and genetics.
Dr. Corcoran and her group have discovered that in young people at risk, stress exposure and cannabis use are associated with symptom severity. Dr. Corcoran has also published on the ethics of high risk research, comorbidity in young people at risk, and the impact of their symptoms on their families, who are frequently key to seeking help.
A primary research goal now in COPE is to understand the basis for social difficulties experienced by young people at COPE, and how best to address these.
COPE is an integral part of the Lieber Center at NYSPI/Columbia, and Dr. Corcoran collaborates actively in translational studies with basic scientists who have developed animal models of psychotic disorders.
Undergraduate: Harvard University, A.B. in Biology, 1985
Graduate: Mailman School of Public Health, M.S. in Biostatistics, 2005
Medical School: Harvard Medical School, M.D., 1990
Internship: The Cambridge Hospital, Transitional, 1990 - 1991
Residency: The Cambridge Hospital, Psychiatry, 1991 - 1994
Fellowship: Columbia University Medical Center, Schizophrenia Research, 1999-2002
Board Certifications: American Board of Psychiatry and Neurology
• Clinical High Risk Research in Psychotic Disorders
• Qualitative Research
Click here for Dr. Corcoran's Clinical Trials
NYS Psychiatric Institute
Room 4804 Unit/Box:2
1051 Riverside Drive
New York, NY 10032
Dr. Corcoran is the Director of the Center of Prevention and Evaluation (COPE), a longitudinal cohort study of young people who are at increased risk for psychosis, as compared to their peers. Her goal is to study this risk state such that we can better understand who is truly at risk and how best to help them.
1. Corcoran CM: Won't Leave His Room: Clinical High Risk for Developing Psychosis; Integrative Perspective, American Psychiatric Publishing, Inc. , Washington DC, , USA, 2009
1. Corcoran C, Malaspina D, Hercher L: Prodromal Interventions for Schizophrenia Vulnerability: the Risks of Being “At Risk”. Schizophrenia Research 2005;73: 173-184
2. Mazzoni P, Kimhy D, Khan S, Posner, K, Maayan L, Eilenberg M, Walsh J, Kestenbaum C, Corcoran C. : Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis.. Journal of Child and Adolescent Psychopharmacology. 2009;19: 771-776
3. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D. : Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis.. Schizophrenia Research. 2008 ;106: 286-93
5. Corcoran C, Davidson L, Sills-Shahar R, Nickou C, Malaspina D, Miller T, McGlashan T
: A qualitative research study of the evolution of symptoms in individuals identified as prodromal to psychosis. Psychiatric Quarterly 2003;74: 313-332